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WONG ET AL.: The Role of Adrenomedullin in the Cardiovascular System. Adrenomedullin (AM) is a 52 amino
acid peptide that was first isolated from human pheochromocytoma. Subsequently, AM and its receptors are found to
be distributed widely in the body, including the cardiovascular system. It belongs to a family of peptides that include
calcitonin gene-related peptide. In blood vessels, AM causes vasodilation and regulates proliferation. It interacts
closely with nitric oxide and has a role in the pathophysiology of hypertension, ischaemic heart disease, cardiac and
renal failure. A non-peptide analogue of AM or gene therapy may be of potential therapeutic use. The role of AM in
septicaemic shock also merits further investigation. (J HK Coll Cardiol 2004;12:75-81)
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Introduction
Adrenomedullin (AM) was first discovered in
1993 by Kitmura and co-workers as a new peptide from
human pheochromocytoma with its ability to raise cyclic
adenosine 3'-5'-monophosphate (cAMP) levels in
platelets.1 Subsequently, AM had aroused much interest
because of its potent and long lasting depressor effect
when injected intravenously into the rat.2 Human AM
consists of 52 amino acids and has a ring structure
formed by one intramolecular disulfide bond and an
amidated carboxyl terminal, structures that are essential
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for its bioactivity. It belongs to a family of peptides
that include calcitonin gene-related peptide (CGRP) and
amylin.3 These peptides bind to either the calcitonin or
the calcitonin receptor-like (CL) receptor.
The human AM gene is located at the single locus
of chromosome 11 and consists of 4 exons and 3 introns.4
In the 5'-upstream sequence of the AM gene, several
binding sites for activator protein-1 and activator
protein-2, cAMP-regulated enhancer and a shear stress
responsive element "GAGACC" are present, which play
roles in the transcriptional regulation of AM gene.3 The
circulating form of AM is formed from successive
enzymatic cleavage of a 185-amino-acid
preproadrenomedullin (preproAM) sequence (Figure 1).
Cleavage of a 20-amino acid sequence in the N-terminal
region of proadrenomedullin yields the
proadrenomedullin N-terminal 20-peptide (PAMP),4
which is also a potent vasodilator. Recently, two other
peptides in the family have been identified, namely
long- and short-form intermedin which consist of a 47-
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Figure 1. Schematic presentation of post-translational processing of the human preproadrenomedullin gene product.

amino acid and a 40-amino acid peptide respectively.5
The long form intermedin is also known as AM2. They
also have vasodilatory and hypotensive actions.

Tissue Distribution and Synthesis
AM was originally identified in pheochromocytoma, however, in the process of identifying
AM-secreting cells, it has been shown to be widely
distributed in many tissues and fluids. Immunoreactive
AM is found in the human cardiovascular, renal,
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respiratory, gastrointestinal, reproductive, neurological,
endocrine and immune systems.6 It circulates in plasma
in the low fmol/ml range, and is also present in urine,
cerebrospinal and amniotic fluid. The plasma half-life
of AM in man is 22 minutes and the volume of
distribution is 880 ml/kg.7
Secretion of AM is influenced by physical and
hormonal factors such as shear stress, ventricular wall
stress, hypoxia, cytokines and endocrine and paracrine
hormones. Inflammatory cytokines including tumour
necrosis factor (TNF)-α, TNF-β, interleukin (IL)-1α,
IL-1β, and lipopolysacccharide (LPS) strongly stimulate
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the synthesis and secretion of AM in endothelial cells
and vascular smooth muscle cells (VSMCs).8 Activation
of NF-IL6 mediates the induction of AM expression by
cytokines. 8 In rat, LPS increases AM expression in
various tissues including lung, heart, liver, and kidney.9 In
VSMCs, AM production is also stimulated by
glucocorticoids, thyroxine, angiotensin II, bradykinin
and adrenaline.10

Receptors and Signal Transduction
Specific binding sites for AM are present in rat
heart, lung, spleen, liver, diaphragm, spinal cord and

different parts of the brain, with the greatest density of
binding sites in the heart and lung.11 Initially, AM was
thought to bind to a CGRP receptor, as these related
peptides have overlapping binding sites and vascular
effects. It is now known that a functional AM or CGRP
receptor consists of at least three proteins: the CL
receptor, receptor-activity-modifying proteins (RAMPs)
and a receptor component protein (RCP). 12 Three
subtypes of RAMPs, namely RAMP1, RAMP2, and
RAMP3, have been identified. CL receptor can function
either as a CGRP receptor or an AM receptor depending
on the co-expression of different subtypes of RAMPs
(Figure 2). Co-expression of CL receptor with RAMP1
forms a CGRP receptor while co-expression of CL

Figure 2. CGRP and AM receptors.
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receptor with RAMP2 or RAMP3 results in binding of
AM. These RAMPs may control the transport and
glycosylation of the CL receptor to define the specificity
of receptor. RAMP1 presents CL receptor as a mature
glycoprotein at the cell surface to form a CGRP receptor,
whereas the RAMP2 or RAMP3-transported receptors
are core glycosylated AM receptors.12
The vasodilatory and hypotensive responses
elicited by AM are mediated via at least two
mechanisms: a direct action on VSMCs to activate the
adenylyl cyclase-PKA pathway resulting in increase of
intracellular cAMP, and an action on endothelial cells
to stimulate nitric oxide (NO) release.13 Furthermore,
potassium ion-ATP channel may also be involved in
AM-induced vasodilation in isolated perfused rat kidney
in which the endothelium-derived hyperpolarizing
factor (EDHF) opens the potassium ion channels.14

Cardiovascular Effects
AM plays a major role in the maintenance of
cardiovascular and renal homeostasis.14,15 In addition, it
modulates the hypertrophy of cardiomyocytes and the
growth of fibroblasts, and also have antimicrobial
effects.4 In transgenic mice with one AM allele deleted,
there was increase in blood pressure and decrease in
NO expression,15 suggesting that AM is involved not
only in blood pressure regulation but also in endothelial
function. Infusion of AM into human brachial artery
significantly increases forearm blood flow via a NOdependent pathway that can be blocked by L-NMMA.16
Infusion of AM in man also lowers pulse wave velocity.17
In sheep, intracoronary AM causes vasodilation, also
through the release of NO.18 In Dahl salt-sensitive rats,
AM restores NO-dependent vasodilatation, through
upregulation of NO production and reduction in
superoxide formation.19
Intravenous infusion of AM lowers blood
pressure, and increases heart rate and cardiac output.20
A direct cardiostimulatory effect can also be
demonstrated in the isolated perfused rat heart. 21
However, AM is also negatively inotropic under other
circumstances, such as in isolated rabbit cardiac
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ventricular myocytes, rat papillary muscle and human
left ventricular myocytes. 22 This negative inotropic
effect may be mediated by NO.
Intravenous infusion of AM increases renal blood
flow, glomerular filtration, urine flow and fractional
urinary sodium excretion, and decreases distal tubular
sodium reabsorption independent of blood pressure.23
The natriuresis and diuresis may be mediated via renal
prostaglandin24 and NO.25
As well as regulating vascular tone, AM may also
regulate vascular proliferation and remodelling. It dosedependently inhibits thymidine incorporation and
proliferation induced by platelet-derived growth factor
in VSMCs.26 AM may also be an angiogenic factor.
Vascular density and endothelial cell proliferation are
stimulated by AM. Many tumours express AM; an
antibody against AM or an AM antagonist suppresses
tumour growth in animal models.27 Whether AM can
be used to increase angiogenesis in ischaemia remains
to be explored.

Neuroendocrine Effects
High levels of AM are found in the adrenal
medulla and zona glomerulosa. Intravenous AM
infusion lowers circulating cortisol and adrenocorticotrophic hormone (ACTH) levels in sheep.28 There
appears to be a complex interaction between AM and
the renin-angiotensin system; AM stimulates the release
of renin,29 but inhibits aldosterone secretion.30
AM immunoreactivity is widely distributed in the
central nervous system (CNS). 31 In the supraoptic
nucleus (SON) and in the magnocellular parts of the
paraventricular nucleus (PVN), AM is expressed. As a
neuropeptide, AM may regulate body fluid homeostasis
by inhibiting water drinking and salt appetite. Blockade
of the action of endogenous AM by passive immunoneutralization results in exaggerated sodium appetite.32
By restraining salt and water intake, AM's central actions
complement its renal actions. AM expression is
increased in the ischemic cerebral cortex in the rat after
middle cerebral artery occlusion,33 where it may increase
cerebral blood flow and promote collateral perfusion.
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Plasma AM Levels in Diseases
Plasma AM levels are increased in a variety of
diseases: congestive heart failure, 34 myocardial
infarction,35 renal diseases,36 hypertension,37 diabetes
mellitus, 38 the acute phase of stroke 39 and septic
shock. 40 Plasma AM levels are elevated in patients
with essential hypertension in proportion to the
severity of hypertension, 36 especially in those with
left ventricular hypertrophy. However, neither acute
nor chronic salt loading, nor anti-hypertensive
therapy changes the circulating level of AM in
patients with essential hypertension. Plasma levels
of AM are increased in patients with congestive heart
failure, whether systolic 34 or diastolic. 41 The failing
human heart secretes increased amounts of AM.
Plasma AM concentration correlates with pulmonary
capillary wedge pressure and inversely with ejection
fraction. It decreases after treatment of the heart
failure. Plasma AM concentration is elevated in
relation to the degree of renal failure.36
Injection of LPS in the rat produces a marked
increase in plasma AM, suggesting AM may be
involved in sepsis. 42 Circulating AM level is also
i n c r e a s e d i n s e p s i s i n m a n . 40 I n t h e e a r l y ,
hyperdynamic phase of septicaemia, there is
upregulation of AM, followed by a reduction in
vascular responsiveness to AM in the late,
hypodynamic response.43 Administration of AM and
its binding protein (AMBP-1) maintains
cardiovascular stability and reduces sepsis-induced
mortality.44 Transgenic mice overexpressing AM are
resistant to septicaemic shock.45 Therefore, AM may
be responsible for many of the changes in the
circulatory system in septic shock.

hypertension and heart failure. In AM-knockout mice,
there is accelerated cardiac hypertrophy and renal
damage induced by angiotensin II,48 suggesting that
endogenous AM protects against cardiac and renal
damages. In the rat model of myocardial infarction
induced by coronary artery ligation, a one-off early
intravenous administration of AM prevents
subsequent left ventricular remodelling.49 As AM is
a peptide, it cannot be given orally. In patients with
pulmonary hypertension, AM administered by
inhalation reduced pulmonary vascular resistance. 50
A non-peptide analogue is eagerly awaited for
clinical studies. Neutral endopeptidase inhibitors
increase the level of AM as well as other vasoactive
peptides, but their use is limited by the increased
likelihood of angiooedema. Expression of AM
is known to be increased after angioplasty and
stenting;51 AM gene delivery successfully inhibited
neointimal formation after balloon angioplasty in a
rat model.52 Gene therapy targeting the AM system
is a novel and promising modality of treatment for
the future.

Conclusions
In summary, AM and its receptor are
distributed widely in the body, including the
cardiovascular system. In blood vessels, AM causes
vasodilation and regulates proliferation. It interacts
closely with NO and has a role in the pathophysiology
of hypertension, ischaemic heart disease, cardiac and
renal failure. A non-peptide analogue of AM or gene
therapy may be of potential use in these diseases.
The role of AM in septicaemic shock, a condition
characterised by high mortality, also merits further
investigation.

AM as Therapeutic Agent
Infusion of AM lowers blood pressure in
hypertension 46 and lowers ventricular end-diastolic
pressure and increases cardiac output in heart failure.47
Therapy based on increased stimulation of AM
receptors may have potential application in
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